Funded Abstract Teardown
NINR advises SBIR and STTR applicants to review sample applications (NINR), but few companies publish theirs. Funded abstracts fill part of that gap. The three awards below come from medical devices, diagnostics and digital health, and each was funded at a different stage, which changes what its abstract had to prove.
Rivanna: Ultrasound Guidance for Pediatric Lumbar Puncture
NCI, R44CA302033, Direct to Phase II, $2.21 million, announced September 2025 (VABio)
Up to 38% of lumbar punctures are traumatic, with blood contaminating the spinal fluid, and the complication is linked to poorer outcomes. Rivanna applies that rate to children who can't avoid the procedure. Acute lymphoblastic leukemia makes up about a quarter of pediatric cancer cases, and a child in treatment may undergo up to 20 lumbar punctures over two years. A risk counted per procedure becomes a burden each patient carries again and again.
The product adds pediatric features to Rivanna's existing Accuro 3S ultrasound platform, using AI to find spinal anatomy and guide the needle. NIH had already funded the company's earlier work on bedside spinal navigation for lumbar puncture, and that record is what supports skipping Phase I. Its aims stay preclinical, testing usability, accuracy and how quickly clinicians learn the system.
Leuko Labs: Needle-Free Neutropenia Monitoring
NCI, 2R44CA228920-04, Phase IIB, $1,702,979 in fiscal 2024 (NIH project record)
Scale comes first. About 850,000 US cancer patients receive chemotherapy each year, and neutropenia costs an estimated $6.4 billion annually. PointCheck images the capillaries under the fingernail to detect severe neutropenia without drawing blood, so patients can check at home between chemotherapy cycles.
Prior evidence is counted in patients, from a 44-patient proof-of-concept study to usability and feasibility studies with 154 and 193 subjects. The remaining aims run from pilot production of 20 units through a 210-patient pivotal study and a Class II De Novo submission to FDA, ending with a 50-patient outcomes study to support reimbursement. After each aim, a reviewer can see exactly where the device will stand with regulators and payers, in a project that began in July 2018.
Nest Genomics: Hereditary Cancer Care Inside the Health Record
NHGRI, STTR, 1R42HG013908-01, $291,643 in fiscal 2024 (NIH project record)
The gap Nest Genomics targets opens after diagnosis. About 4% of the US population carries inherited cancer risk, and identifying those patients has improved, but long-term care lags behind. Uptake of recommended surveillance ranges from 52% to 85% depending on the test, and uptake of risk-reducing surgery ranges from 9% to 65%. Adherence falls over time, and it falls fastest among adolescents and young adults moving between schools, jobs and clinicians.
Hereditary cancer was a deliberate starting point. Testing for it is guideline-recommended and well covered by payers. The platform stores structured genetic results in the electronic medical record and gives clinicians decision support for guideline-based care plans. It also automates charting and adds a mobile tool for patients. The public record cuts off before the full list of aims.
Search NIH RePORTER by your target institute and activity code for recent awards in your product category, and note which numbers each abstract puts in its opening lines.